Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O Trial

Over the past two decades, the overall incidence of chemotherapy-induced nausea and vomiting (CINV) has improved with greater insight into physiologic pathways and subsequent novel drug development. Namely, the development of 5-HT3 receptor antagonists in the early 1990 ’s followed by NK-1 receptor antagonist in the early 2000’s significantly improved acute and delayed CINV outcomes [1]. Despite proper implementation of these pharmacologic agents as well as non-pharmacologic methods for prophylaxis, CINV - particularly nausea, remains a clinically significant s ide effect for patients receiving moderately and highly emetogenic chemotherapy (MEC and HEC, respectively) [2,3].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research